<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24623423</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice.</ArticleTitle><Pagination><StartPage>5803</StartPage><EndPage>5815</EndPage><MedlinePgn>5803-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00289-14</ELocationID><Abstract><AbstractText Label="UNLABELLED">In a screen for ribavirin resistance, a novel high-fidelity variant of human enterovirus 71 (EV71) with the single amino acid change L123F in its RNA-dependent RNA polymerase (RdRp or 3D) was identified. Based on the crystal structure of EV71 RdRp, L123 locates at the entrance of the RNA template binding channel, which might form a fidelity checkpoint. EV71 RdRp-L123F variants generated less progeny in a guanidine resistance assay and virus populations with lower mutation frequencies in cell culture passage due to their higher replication fidelity. However, compared with wild-type viruses, they did not show growth defects. In vivo infections further revealed that high-fidelity mutations L123F and G64R (previously reported) negatively impacted EV71 fitness and greatly reduced viral pathogenicity alone or together in AG129 mice. Interestingly, a variant with double mutations, RG/B4-G64R/L123F (where RG/B4 is an EV71 genotype B4 virus constructed by reverse genetics [RG])showed higher fidelity in vitro and less virulence in vivo than any one of the above two single mutants. The 50% lethal dose (LD50) of the double mutant increased more than 500 times compared with the LD50 of wild-type RG/B4 in mice. The results indicated that these high-fidelity variants exhibited an attenuated pathogenic phenotype in vivo and offer promise as a live attenuated EV71 vaccine.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">The error-prone nature of the RNA-dependent RNA polymerase (RdRp) of RNA viruses during replication results in quasispecies and aids survival of virus populations under a wide range of selective pressures. Virus variants with higher replication fidelity exhibit lower genetic diversity and attenuated pathogenicity in vivo. Here, we identified a novel high-fidelity mutation L123F in the RdRp of human enterovirus 71 (EV71). We further elucidated that EV71 variants with the RdRp-L123F mutation and/or the previously identified high-fidelity mutation RdRp-G64R were attenuated in an AG129 mouse model. As EV71 has emerged as a serious worldwide health threat, especially in developing countries in the Asia-Pacific region, we urgently need EV71 vaccines. Learning from the poliovirus vaccination, we prefer live attenuated EV71 vaccines to inactivated EV71 vaccines in order to effectively control EV71 outbreaks at low cost. Our results imply a new means of attenuating EV71 and reducing its mutation rate at the same time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwang</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA-Dependent RNA Polymerase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007928" MajorTopicYN="N">Lethal Dose 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="N">RNA-Dependent RNA Polymerase</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012692" MajorTopicYN="N">Serial Passage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24623423</ArticleId><ArticleId IdType="pmc">PMC4019108</ArticleId><ArticleId IdType="doi">10.1128/JVI.00289-14</ArticleId><ArticleId IdType="pii">JVI.00289-14</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Domingo E, Sabo D, Taniguchi T, Weissmann C. 1978. Nucleotide sequence heterogeneity of an RNA phage population. Cell 13:735&#x2013;744. 10.1016/0092-8674(78)90223-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(78)90223-4</ArticleId><ArticleId IdType="pubmed">657273</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggers HJ, Tamm I. 1965. Coxsackie A9 virus: mutation from drug dependence to drug independence. Science 148:97&#x2013;98. 10.1126/science.148.3666.97</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.148.3666.97</ArticleId><ArticleId IdType="pubmed">14258734</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E, Wain-Hobson S. 2009. The 30th anniversary of quasispecies. Meeting on &#x201c;Quasispecies: past, present and future.&#x201d; EMBO Rep. 10:444&#x2013;448. 10.1038/embor.2009.61</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2009.61</ArticleId><ArticleId IdType="pmc">PMC2680878</ArticleId><ArticleId IdType="pubmed">19343047</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E, Holland JJ. 1997. A virus mutations and fitness for survival. Annu. Rev. Microbiol. 51:151&#x2013;178. 10.1146/annurev.micro.51.1.151</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.51.1.151</ArticleId><ArticleId IdType="pubmed">9343347</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake JW, Charlesworth B, Charlesworth D, Crow JF. 1998. Rates of spontaneous mutation. Genetics 148:1667&#x2013;1686</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1460098</ArticleId><ArticleId IdType="pubmed">9560386</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE. 2000. The broad spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:1375&#x2013;1379. 10.1038/82191</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/82191</ArticleId><ArticleId IdType="pubmed">11100123</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U. S. A. 98:6895&#x2013;6900. 10.1073/pnas.111085598</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.111085598</ArticleId><ArticleId IdType="pmc">PMC34449</ArticleId><ArticleId IdType="pubmed">11371613</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer JK, Kirkegaard K. 2003. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U. S. A. 100:7289&#x2013;7294. 10.1073/pnas.1232294100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1232294100</ArticleId><ArticleId IdType="pmc">PMC165868</ArticleId><ArticleId IdType="pubmed">12754380</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi LI, Gn&#xe4;dig NF, Beaucourt S, McPherson MJ, Baron B, Arnold JJ, Vignuzzi M. 2010. Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds. PLoS Pathog. 6:e1001163. 10.1371/journal.ppat.1001163</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001163</ArticleId><ArticleId IdType="pmc">PMC2965762</ArticleId><ArticleId IdType="pubmed">21060812</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffey LL, Beeharry Y, Border&#xed;a AV, Blanc H, Vignuzzi M. 2011. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc. Natl. Acad. Sci. U. S. A. 108:16038&#x2013;16043. 10.1073/pnas.1111650108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1111650108</ArticleId><ArticleId IdType="pmc">PMC3179076</ArticleId><ArticleId IdType="pubmed">21896755</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer JK, Kirkegaard K. 2005. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog. 1:e11. 10.1371/journal.ppat.0010011</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.0010011</ArticleId><ArticleId IdType="pmc">PMC1250929</ArticleId><ArticleId IdType="pubmed">16220146</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344&#x2013;348. 10.1038/nature04388</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04388</ArticleId><ArticleId IdType="pmc">PMC1569948</ArticleId><ArticleId IdType="pubmed">16327776</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignuzzi M, Wendt E, Andino R. 2008. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 14:154&#x2013;161. 10.1038/nm1726</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1726</ArticleId><ArticleId IdType="pubmed">18246077</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. 1974. An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 129:304&#x2013;309. 10.1093/infdis/129.3.304</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 10:778&#x2013;790. 10.1016/S1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, Tong CY, Takebe Y, Pybus OG. 2010. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J. Virol. 84:3339&#x2013;3350. 10.1128/JVI.01019-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01019-09</ArticleId><ArticleId IdType="pmc">PMC2838098</ArticleId><ArticleId IdType="pubmed">20089660</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF. 1999. Neurologic complications in children with enterovirus infection. N. Engl. J. Med. 341:936&#x2013;942. 10.1056/NEJM199909233411302</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411302</ArticleId><ArticleId IdType="pubmed">10498488</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. 2010. Clinical features, diagnosis and management of human enterovirus 71 infection. Lancet Neurol. 9:1097&#x2013;1105. 10.1016/S1474-4422(10)70209-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang J. 2013. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum. Vaccin Immunother. 9:1701&#x2013;1705. 10.4161/hv.24949</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24949</ArticleId><ArticleId IdType="pmc">PMC3906269</ArticleId><ArticleId IdType="pubmed">23744508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL. 2013. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381:2024&#x2013;2032. 10.1016/S0140-6736(13)61049-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF, Mao QY, Wen SQ, Huang RG, Hu YS, Yao X, Miao X, Wu X, Li RC, Wang JZ, Yin WD. 2014. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 (EV71) vaccine: a phase II, randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 209:46&#x2013;55. 10.1093/infdis/jit429</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit429</ArticleId><ArticleId IdType="pubmed">23922377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Cochi SL, Melnick JL. 1999. Live-attenuated poliovirus vaccine. Saunders, Philadelphia, PA</Citation></Reference><Reference><Citation>Zinkernagel RM. 2003. On natural and artificial vaccinations. Annu. Rev. Immunol. 21:515&#x2013;546. 10.1146/annurev.immunol.21.120601.141045</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.21.120601.141045</ArticleId><ArticleId IdType="pubmed">12500980</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert PH, Liu M, Siegrist CA. 2005. Can. successful vaccines teach us how to induce efficient protective immune responses? Nat. Med. 11(4 Suppl):S54&#x2013;S62. 10.1038/nm1216</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1216</ArticleId><ArticleId IdType="pubmed">15812491</ArticleId></ArticleIdList></Reference><Reference><Citation>Salerno-Gon&#xe7;alves R, Sztein MB. 2006. Cell-mediated immunity and the challenges for vaccine development. Trends Microbiol. 14:536&#x2013;542. 10.1016/j.tim.2006.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2006.10.004</ArticleId><ArticleId IdType="pubmed">17055276</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YC, Yu CK, Wang YF, Liu CC, Su IJ, Lei HY. 2004. A murine oral enterovirus 71 infection model with central nervous system involvement. J. Gen. Virol. 85:69&#x2013;77. 10.1099/vir.0.19423-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.19423-0</ArticleId><ArticleId IdType="pubmed">14718621</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua BH, Phuektes P, Sanders SA, Nicholls PK, McMinn PC. 2008. The molecular basis of mouse adaptation by human enterovirus 71. J. Gen. Virol. 89:1622&#x2013;1632. 10.1099/vir.0.83676-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.83676-0</ArticleId><ArticleId IdType="pubmed">18559932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Duo J, Liu J, Ma C, Zhang Wei L Q, Qin C. 2011. A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice. Microbes Infect. 13:862&#x2013;870. 10.1016/j.micinf.2011.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2011.04.004</ArticleId><ArticleId IdType="pubmed">21612764</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Ami Y, Wakita T, Shimizu H. 2008. Cooperative effect of the attenuation determinants derived from poliovirus Sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J. Virol. 82:1787&#x2013;1797. 10.1128/JVI.01798-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01798-07</ArticleId><ArticleId IdType="pmc">PMC2258712</ArticleId><ArticleId IdType="pubmed">18057246</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, Chow VT, Alonso S. 2012. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J. Virol. 86:2121&#x2013;2131. 10.1128/JVI.06103-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06103-11</ArticleId><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Yu SL, Shao HY, Lin HY, Liu CC, Hsiao KN, Chitra E, Tsou YL, Chang HW, Sia C, Chong P, Chow YH. 2013. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One 8:e57591. 10.1371/journal.pone.0057591</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057591</ArticleId><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Nagata N, Sato Y, Ong KC, Wong KT, Yamayoshi S, Shimanuki M, Shitara H, Taya C, Koike S. 2013. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc. Natl. Acad. Sci. U. S. A. 110:14753&#x2013;14758. 10.1073/pnas.1217563110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1217563110</ArticleId><ArticleId IdType="pmc">PMC3767555</ArticleId><ArticleId IdType="pubmed">23959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour S, Bek EJ, McMinn PC. 2013. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J. Virol. 87:1759&#x2013;1769. 10.1128/JVI.02139-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02139-12</ArticleId><ArticleId IdType="pmc">PMC3554166</ArticleId><ArticleId IdType="pubmed">23175376</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour S, McMinn PC. 2013. A study of the virulence in mice of high copying fidelity variants of human enterovirus 71. Virus Res. 176:265&#x2013;272. 10.1016/j.virusres.2013.06.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2013.06.019</ArticleId><ArticleId IdType="pmc">PMC7114468</ArticleId><ArticleId IdType="pubmed">23856384</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kolpe AB, Kiener TK, Chow VT, Kwang J. 2011. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS One 6:e21757. 10.1371/journal.pone.0021757</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021757</ArticleId><ArticleId IdType="pmc">PMC3128602</ArticleId><ArticleId IdType="pubmed">21747954</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Lou Z, Miao Y, Yu Y, Dong H, Peng W, Bartlam M, Li X, Rao Z. 2010. Structures of EV71 RNA-dependent RNA polymerase in complex with substrate and analogue provide a drug target against the hand-foot-and-mouth disease pandemic in China. Protein Cell 1:491&#x2013;500. 10.1007/s13238-010-0061-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-010-0061-7</ArticleId><ArticleId IdType="pmc">PMC4875138</ArticleId><ArticleId IdType="pubmed">21203964</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kiener TK, Kwang J. 2012. RNA polymerase I-driven reverse genetics system for enterovirus 71 and its implications for vaccine production. Virol. J. 9:238&#x2013;245. 10.1186/1743-422X-9-238</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-238</ArticleId><ArticleId IdType="pmc">PMC3493273</ArticleId><ArticleId IdType="pubmed">23072515</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour S, Bek EJ, McMinn PC. 2012. Selection and characterisation of guanidine resistant mutants of human enterovirus 71. Virus Res. 169:72&#x2013;79. 10.1016/j.virusres.2012.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2012.07.005</ArticleId><ArticleId IdType="pubmed">22814431</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra M, Airaksinen A, Gonz&#xe1;lez-L&#xf3;pez C, Agudo R, Arias A, Domingo E. 2007. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J. Virol. 81:2012&#x2013;2024. 10.1128/JVI.01606-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01606-06</ArticleId><ArticleId IdType="pmc">PMC1797574</ArticleId><ArticleId IdType="pubmed">17151116</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AA, Peersen OB. 2004. Structural basis for proteolysis-dependent activation of the poliovirus RNA-dependent RNA polymerase. EMBO J. 23:3462&#x2013;3471. 10.1038/sj.emboj.7600357</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600357</ArticleId><ArticleId IdType="pmc">PMC516629</ArticleId><ArticleId IdType="pubmed">15306852</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold JJ, Vignuzzi M, Stone JK, Andino Cameron R CE. 2005. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J. Biol. Chem. 280:25706&#x2013;25716. 10.1074/jbc.M503444200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M503444200</ArticleId><ArticleId IdType="pmc">PMC1557591</ArticleId><ArticleId IdType="pubmed">15878882</ArticleId></ArticleIdList></Reference><Reference><Citation>Gn&#xe4;dig NF, Beaucourt S, Campagnola G, Border&#xed;a AV, Sanz-Ramos M, Gong P, Blanc H, Peersen OB, Vignuzzi M. 2012. Coxsackievirus B3 mutator strains are attenuated in vivo. Proc. Natl. Acad. Sci. U. S. A. 109:E2294&#x2013;E2303. 10.1073/pnas.1204022109</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1204022109</ArticleId><ArticleId IdType="pmc">PMC3427060</ArticleId><ArticleId IdType="pubmed">22853955</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Z, Asher DM, Levenbook IS, Chumakov KM. 1996. Succession of mutations in the Sabin strain of type 3 poliovirus replicating in the central nervous system of monkeys. Virology 220:285&#x2013;289. 10.1006/viro.1996.0316</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1996.0316</ArticleId><ArticleId IdType="pubmed">8661379</ArticleId></ArticleIdList></Reference><Reference><Citation>Glushakova S, Grivel JC, Fitzgerald W, Sylwester A, Zimmerberg J, Margolis LB. 1998. Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nat. Med. 4:346&#x2013;349. 10.1038/nm0398-346</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0398-346</ArticleId><ArticleId IdType="pubmed">9500611</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordey S, Petty TJ, Schibler M, Martinez Y, Gerlach D, van Belle S, Turin L, Zdobnov E, Kaiser L, Tapparel C. 2012. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog. 8:e1002826. 10.1371/journal.ppat.1002826</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002826</ArticleId><ArticleId IdType="pmc">PMC3406088</ArticleId><ArticleId IdType="pubmed">22910880</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan D, van der Sanden S, Zeng H, Li W, Zheng Ma H C, Su J, Liu Z, Guo X, Zhang X, Liu L, Koopmans M, Ke C. 2012. Population dynamics and genetic diversity of C4 strains of human enterovirus 71 in Mainland China, 1998&#x2013;2010. PLoS One 7:e44386. 10.1371/journal.pone.0044386</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044386</ArticleId><ArticleId IdType="pmc">PMC3440427</ArticleId><ArticleId IdType="pubmed">22984501</ArticleId></ArticleIdList></Reference><Reference><Citation>Perales C, Iranzo J, Manrubia SC, Domingo E. 2012. The impact of quasispecies dynamics on the use of therapeutics. Trends Microbiol. 20:595&#x2013;603. 10.1016/j.tim.2012.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2012.08.010</ArticleId><ArticleId IdType="pubmed">22989762</ArticleId></ArticleIdList></Reference><Reference><Citation>Guti&#xe9;rrez S, Michalakis Y, Blanc S. 2012. Virus population bottlenecks during within-host progression and host-to-host transmission. Curr. Opin. Virol. 2:546&#x2013;555. 10.1016/j.coviro.2012.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2012.08.001</ArticleId><ArticleId IdType="pubmed">22921636</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhao H, Zhang Y, Wang J, Che Dong Y C, Zhang X, Na R, Shi H, Jiang L, Wang L, Xie Z, Cui P, Xiong X, Liao Y, Zhao S, Gao J, Tang D, Li Q. 2011. Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection. Virology 412:91&#x2013;100. 10.1016/j.virol.2010.12.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2010.12.058</ArticleId><ArticleId IdType="pubmed">21262515</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>